-
Masitinib is Showing Signs of Slowing Progression of ALS in Phase 2/3 Trial
ALS News Today’s Director of Multichannel Content, Michael Morale, discusses how the add-on Masitinib is showing signs of slowing progression of ALS in a phase 2/3 trial.
Are you interested in learning more about ALS? If so, please visit alsnewstoday.com/
What are your thoughts on this news?
-
1 Reply
-
My thoughts are these:
1) It’s exciting to hear of a drug that has been shown to slow progression by 27% with no adverse side effects.
2) Phase 3 began in May, 2019, but, according to ClinicalTrials.gov, will not reach completion until 2024. Mastinib was shown to slow progression by 25% at least two years ago:
3) Perhaps someone more knowledgeable about trials than I am might be willing to explain why trials like these must take as long as seven years.
4) I would be interested to know if any forum members may have considered the Right to Try Act in order to obtain access to a promising drug before it’s been approved by the FDA: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try
Thank you.
Log in to reply.